RATIONALE: The D6 chemokine receptor can bind and scavenge several chemokines, including the T-helper 2 (Th2)-associated chemokines CCL17 and CCL22. Although D6 is constitutively expressed in the lung, its pulmonary function is unknown. OBJECTIVES: This study tested whether D6 regulates pulmonary chemokine levels, inflammation, or airway responsiveness during allergen-induced airway disease. METHODS: D6-deficient and genetically matched C57BL/6 mice were sensitized and challenged with ovalbumin. ELISA and flow cytometry were used to measure levels of cytokines and leukocytes, respectively. Mechanical ventilation was used to measure airway reactivity. RESULTS: The ability of D6 to diminish chemokine levels in the lung was chemokine concentration dependent. CCL17 and CCL22 were abundant in the airway, and their levels were attenuated by D6 when they were within a defined concentration range. By contrast, airway concentrations of CCL3, CCL5, and CCL11 were low and unaffected by D6. Allergen-challenged D6-deficient mice had more dendritic cells, T cells, and eosinophils in the lung parenchyma and more eosinophils in the airway than similarly challenged C57BL/6 mice. By contrast, D6-deficient mice had reduced airway responses to methacholine compared with C57BL/6 mice. Thus, D6 has opposing effects on inflammation and airway reactivity. CONCLUSIONS: The ability of D6 to scavenge chemokines in the lung is dependent on chemokine concentration. The absence of D6 increases inflammation, but reduces airway reactivity. These findings suggest that inhibiting D6 function might be a novel means to attenuate airway responses in individuals with allergic asthma.
RATIONALE: The D6 chemokine receptor can bind and scavenge several chemokines, including the T-helper 2 (Th2)-associated chemokines CCL17 and CCL22. Although D6 is constitutively expressed in the lung, its pulmonary function is unknown. OBJECTIVES: This study tested whether D6 regulates pulmonary chemokine levels, inflammation, or airway responsiveness during allergen-induced airway disease. METHODS: D6-deficient and genetically matched C57BL/6 mice were sensitized and challenged with ovalbumin. ELISA and flow cytometry were used to measure levels of cytokines and leukocytes, respectively. Mechanical ventilation was used to measure airway reactivity. RESULTS: The ability of D6 to diminish chemokine levels in the lung was chemokine concentration dependent. CCL17 and CCL22 were abundant in the airway, and their levels were attenuated by D6 when they were within a defined concentration range. By contrast, airway concentrations of CCL3, CCL5, and CCL11 were low and unaffected by D6. Allergen-challenged D6-deficient mice had more dendritic cells, T cells, and eosinophils in the lung parenchyma and more eosinophils in the airway than similarly challenged C57BL/6 mice. By contrast, D6-deficient mice had reduced airway responses to methacholine compared with C57BL/6 mice. Thus, D6 has opposing effects on inflammation and airway reactivity. CONCLUSIONS: The ability of D6 to scavenge chemokines in the lung is dependent on chemokine concentration. The absence of D6 increases inflammation, but reduces airway reactivity. These findings suggest that inhibiting D6 function might be a novel means to attenuate airway responses in individuals with allergic asthma.
Authors: G Hansen; J J McIntire; V P Yeung; G Berry; G J Thorbecke; L Chen; R H DeKruyff; D T Umetsu Journal: J Clin Invest Date: 2000-01 Impact factor: 14.808
Authors: S H Gavett; S L Madison; P C Chulada; P E Scarborough; W Qu; J E Boyle; H F Tiano; C A Lee; R Langenbach; V L Roggli; D C Zeldin Journal: J Clin Invest Date: 1999-09 Impact factor: 14.808
Authors: T Imai; M Nagira; S Takagi; M Kakizaki; M Nishimura; J Wang; P W Gray; K Matsushima; O Yoshie Journal: Int Immunol Date: 1999-01 Impact factor: 4.823
Authors: M Kitaura; N Suzuki; T Imai; S Takagi; R Suzuki; T Nakajima; K Hirai; H Nomiyama; O Yoshie Journal: J Biol Chem Date: 1999-09-24 Impact factor: 5.157
Authors: R Godiska; D Chantry; C J Raport; S Sozzani; P Allavena; D Leviten; A Mantovani; P W Gray Journal: J Exp Med Date: 1997-05-05 Impact factor: 14.307
Authors: Rhonda H Wilson; Gregory S Whitehead; Hideki Nakano; Meghan E Free; Jay K Kolls; Donald N Cook Journal: Am J Respir Crit Care Med Date: 2009-08-06 Impact factor: 21.405
Authors: Jeffrey W Card; Michelle A Carey; James W Voltz; J Alyce Bradbury; Catherine D Ferguson; Eric A Cohen; Samuel Schwartz; Gordon P Flake; Daniel L Morgan; Samuel J Arbes; David A Barrow; Silvana P Barros; Steven Offenbacher; Darryl C Zeldin Journal: Infect Immun Date: 2010-03-22 Impact factor: 3.441
Authors: Antal Rot; Clive McKimmie; Claire L Burt; Kenneth J Pallas; Thomas Jamieson; Monika Pruenster; Richard Horuk; Robert J B Nibbs; Gerard J Graham Journal: J Immunol Date: 2013-05-13 Impact factor: 5.422
Authors: Yvonne Bordon; Chris A H Hansell; David P Sester; Mairi Clarke; Allan McI Mowat; Robert J B Nibbs Journal: J Immunol Date: 2009-04-15 Impact factor: 5.422
Authors: Robert J B Nibbs; Derek S Gilchrist; Vicky King; Antonio Ferra; Steve Forrow; Keith D Hunter; Gerard J Graham Journal: J Clin Invest Date: 2007-07 Impact factor: 14.808
Authors: Mark D Singh; Vicky King; Helen Baldwin; David Burden; Anne Thorrat; Susan Holmes; Iain B McInnes; Ruairidh Nicoll; Kave Shams; Kenneth Pallas; Thomas Jamieson; Kit Ming Lee; Jose M Carballido; Antal Rot; Gerard J Graham Journal: Am J Pathol Date: 2012-08-04 Impact factor: 4.307
Authors: Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik Journal: Pharmacol Rev Date: 2013-11-11 Impact factor: 25.468